DHR vs. HALO: Danaher vs. Halozyme Therapeutics Stock Comparison

November 11, 2026

How do Danaher (DHR) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Danaher (DHR) and Halozyme Therapeutics (HALO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while HALO is classified in Biotechnology.

Company profile comparison for Danaher (DHR) and Halozyme Therapeutics (HALO)
Profile Item	DHR	HALO
Name	Danaher Corp.	Halozyme Therapeutics Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	161.86 billion USD	11.81 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	December 29, 1978	March 16, 2004
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

DHR

HALO

GSPC

Danaher (DHR) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Danaher (DHR) and Halozyme Therapeutics (HALO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Danaher (DHR) and Halozyme Therapeutics (HALO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
Total Return (1Y)	11.88%	50.94%
Total Return (3Y, Annualized)	6.67%	41.08%
Total Return (5Y, Annualized)	-2.05%	21.68%

Risk Profile

Drawdown History

DHR

HALO

GSPC

Danaher (DHR) vs. Halozyme Therapeutics (HALO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Danaher (DHR) and Halozyme Therapeutics (HALO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
Volatility (1Y, Annualized)	30.61%	41.19%
Beta (5Y)	0.76	0.96
Max Drawdown (5Y)	-43.31%	-49.06%
Avg. Volume (3M)	3.94M	2.29M

Risk-Adjusted Performance

Risk-Return Positioning

DHR and HALO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
Sharpe Ratio (1Y)	0.25	1.13
Sortino Ratio (1Y)	0.35	1.78

Profitability

ROE (TTM)

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Danaher (DHR) at 8.19% also sits in the top quartile.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 109.18%
DHR: 8.19%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO: 216.38%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and Danaher (DHR) at 16.91% also retains a top-quartile share.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max: 18.05%
DHR: 16.91%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO: 26.93%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Danaher (DHR) at 21.13% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max: 83.12%
DHR: 21.13%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Max: 83.12%
HALO: 59.84%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
ROE (TTM)	8.19%	216.38%
ROA (TTM)	4.06%	22.42%
Net Margin (TTM)	16.91%	26.93%
Operating Margin (TTM)	21.13%	59.84%
Gross Margin (TTM)	59.36%	77.74%

Growth

Revenue Growth

Both Danaher (DHR) at 2.90% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Danaher (DHR) at -4.54% and Halozyme Therapeutics (HALO) at -25.36% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
Revenue Growth (YoY)	2.90%	37.55%
Revenue Growth (3Y CAGR)	-2.67%	28.38%
EPS Growth (YoY)	-4.54%	-25.36%
EPS Growth (3Y CAGR)	-19.44%	21.14%

Financial Strength

Current Ratio (MRQ)

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
DHR: 1.63
Min: 0.10

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max: 25.13
Q3: 12.13
Median: 5.52
HALO: 3.88
Q1: 2.47
Min: 0.10

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Danaher (DHR) carries debt-to-equity ratio of 0.52 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max: 1.42
Q3: 0.65
DHR: 0.52
Median: 0.15
Q1: 0.02
Min: 0.00

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
HALO: --

Danaher (DHR) vs. Halozyme Therapeutics (HALO): HALO does not report debt-to-equity ratio, so it has no value marker; DHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
Current Ratio (MRQ)	1.63	3.88
Debt / Equity (MRQ)	0.52	--
Net Debt / EBITDA	2.68	1.90

Dividends

Dividend Yield (TTM)

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR: 0.67%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR: 25.17%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
Dividend Yield (TTM)	0.67%	0.00%
Dividend Payout Ratio (TTM)	25.17%	0.00%

Valuation

P/E Ratio (TTM)

Both Danaher (DHR) at 38.12 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max: 85.34
Q3: 43.46
DHR: 38.12
Median: 26.69
Q1: 13.30
Min: 0.07

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Max: 85.34
Q3: 43.46
Median: 26.69
HALO: 25.91
Q1: 13.30
Min: 0.07

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Danaher (DHR) at 6.32 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max: 58.18
Q3: 25.77
Median: 7.30
DHR: 6.32
Q1: 3.01
Min: 0.01

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max: 58.18
Q3: 25.77
Median: 7.30
HALO: 6.55
Q1: 3.01
Min: 0.01

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Danaher (DHR) reports 3.02, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max: 13.53
Q3: 6.54
Median: 3.25
DHR: 3.02
Q1: 1.69
Min: -5.59

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
HALO: -213.67

Danaher (DHR) vs. Halozyme Therapeutics (HALO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Danaher (DHR) and Halozyme Therapeutics (HALO)
Metric	DHR	HALO
P/E Ratio (TTM)	38.12	25.91
P/S Ratio (TTM)	6.32	6.55
P/B Ratio (MRQ)	3.02	-213.67
Free Cash Flow Yield (TTM)	2.93%	3.48%